Cargando…

Découverte de Foyers de Poliovirus de Type-2 Dérivé du Vaccin Antipoliomyélitique Oral en République Centrafricaine en 2019

OBJECTIVE: In 2019, the Central African Republic identified foci of circulating vaccine-derived poliovirus 2 (PVDV2c). The objective of this work is to describe the vaccination status of children paralyzed by PVDV2c and their contacts and to assess the circulation of this strain in these contacts. P...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalthan, E., Gouandjika-Vasilache, I., Mbailao, R., Doté, J.W., Kossone, M.N., Gbangai, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MTSI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022749/
https://www.ncbi.nlm.nih.gov/pubmed/35586583
http://dx.doi.org/10.48327/mtsibulletin.2021.114
_version_ 1784690148715266048
author Kalthan, E.
Gouandjika-Vasilache, I.
Mbailao, R.
Doté, J.W.
Kossone, M.N.
Gbangai, M.
author_facet Kalthan, E.
Gouandjika-Vasilache, I.
Mbailao, R.
Doté, J.W.
Kossone, M.N.
Gbangai, M.
author_sort Kalthan, E.
collection PubMed
description OBJECTIVE: In 2019, the Central African Republic identified foci of circulating vaccine-derived poliovirus 2 (PVDV2c). The objective of this work is to describe the vaccination status of children paralyzed by PVDV2c and their contacts and to assess the circulation of this strain in these contacts. PATIENTS AND METHOD: The study population of this retrospective survey consists of children with acute flaccid paralysis (AFP) and their contacts. We included paralyzed children whose sequencing results showed the presence of PVDV2c. RESULTS: A total of 21 children paralyzed by PVDVc and 64 contacts were enrolled in the survey. Fourteen out of 21 children who are paralyzed (66%) received at least one dose of bivalent oral polio vaccine (OPV) compared to 36 out of 64 contacts (57%, non-significant difference). Of the vaccinated patients, 7 had received less than three doses. For the injectable polio vaccine (IPV), vaccination coverage for both patients and contacts was 33%. The proportion of children who received both doses of OPV and IPV was 33% among patients and 25% in contacts. Contacts with VDPV2 were vaccinated with OPV and IPV, respectively 55 and 27%. VDPV2 and Sabin 2 were also found in contact stools, 34% and 9% respectively. CONCLUSION: The absence or inadequacy of IPV vaccination has a serious impact on children by the occurrence of virus derived from the vaccine responsible for life-old paralysis. Protecting children from poliomyelitis requires a combination of a good cold chain, multiple doses and adherence to the vaccine schedule.
format Online
Article
Text
id pubmed-9022749
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MTSI
record_format MEDLINE/PubMed
spelling pubmed-90227492022-05-17 Découverte de Foyers de Poliovirus de Type-2 Dérivé du Vaccin Antipoliomyélitique Oral en République Centrafricaine en 2019 Kalthan, E. Gouandjika-Vasilache, I. Mbailao, R. Doté, J.W. Kossone, M.N. Gbangai, M. Med Trop Sante Int Virologie OBJECTIVE: In 2019, the Central African Republic identified foci of circulating vaccine-derived poliovirus 2 (PVDV2c). The objective of this work is to describe the vaccination status of children paralyzed by PVDV2c and their contacts and to assess the circulation of this strain in these contacts. PATIENTS AND METHOD: The study population of this retrospective survey consists of children with acute flaccid paralysis (AFP) and their contacts. We included paralyzed children whose sequencing results showed the presence of PVDV2c. RESULTS: A total of 21 children paralyzed by PVDVc and 64 contacts were enrolled in the survey. Fourteen out of 21 children who are paralyzed (66%) received at least one dose of bivalent oral polio vaccine (OPV) compared to 36 out of 64 contacts (57%, non-significant difference). Of the vaccinated patients, 7 had received less than three doses. For the injectable polio vaccine (IPV), vaccination coverage for both patients and contacts was 33%. The proportion of children who received both doses of OPV and IPV was 33% among patients and 25% in contacts. Contacts with VDPV2 were vaccinated with OPV and IPV, respectively 55 and 27%. VDPV2 and Sabin 2 were also found in contact stools, 34% and 9% respectively. CONCLUSION: The absence or inadequacy of IPV vaccination has a serious impact on children by the occurrence of virus derived from the vaccine responsible for life-old paralysis. Protecting children from poliomyelitis requires a combination of a good cold chain, multiple doses and adherence to the vaccine schedule. MTSI 2021-06-20 /pmc/articles/PMC9022749/ /pubmed/35586583 http://dx.doi.org/10.48327/mtsibulletin.2021.114 Text en Copyright © 2021 SFMTSI https://creativecommons.org/licenses/by/4.0/Cet article en libre accès est distribué selon les termes de la licence Creative Commons CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Virologie
Kalthan, E.
Gouandjika-Vasilache, I.
Mbailao, R.
Doté, J.W.
Kossone, M.N.
Gbangai, M.
Découverte de Foyers de Poliovirus de Type-2 Dérivé du Vaccin Antipoliomyélitique Oral en République Centrafricaine en 2019
title Découverte de Foyers de Poliovirus de Type-2 Dérivé du Vaccin Antipoliomyélitique Oral en République Centrafricaine en 2019
title_full Découverte de Foyers de Poliovirus de Type-2 Dérivé du Vaccin Antipoliomyélitique Oral en République Centrafricaine en 2019
title_fullStr Découverte de Foyers de Poliovirus de Type-2 Dérivé du Vaccin Antipoliomyélitique Oral en République Centrafricaine en 2019
title_full_unstemmed Découverte de Foyers de Poliovirus de Type-2 Dérivé du Vaccin Antipoliomyélitique Oral en République Centrafricaine en 2019
title_short Découverte de Foyers de Poliovirus de Type-2 Dérivé du Vaccin Antipoliomyélitique Oral en République Centrafricaine en 2019
title_sort découverte de foyers de poliovirus de type-2 dérivé du vaccin antipoliomyélitique oral en république centrafricaine en 2019
topic Virologie
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022749/
https://www.ncbi.nlm.nih.gov/pubmed/35586583
http://dx.doi.org/10.48327/mtsibulletin.2021.114
work_keys_str_mv AT kalthane decouvertedefoyersdepoliovirusdetype2deriveduvaccinantipoliomyelitiqueoralenrepubliquecentrafricaineen2019
AT gouandjikavasilachei decouvertedefoyersdepoliovirusdetype2deriveduvaccinantipoliomyelitiqueoralenrepubliquecentrafricaineen2019
AT mbailaor decouvertedefoyersdepoliovirusdetype2deriveduvaccinantipoliomyelitiqueoralenrepubliquecentrafricaineen2019
AT dotejw decouvertedefoyersdepoliovirusdetype2deriveduvaccinantipoliomyelitiqueoralenrepubliquecentrafricaineen2019
AT kossonemn decouvertedefoyersdepoliovirusdetype2deriveduvaccinantipoliomyelitiqueoralenrepubliquecentrafricaineen2019
AT gbangaim decouvertedefoyersdepoliovirusdetype2deriveduvaccinantipoliomyelitiqueoralenrepubliquecentrafricaineen2019